Clearpoint Neuro (CLPT) Q2 2024 earnings summary

Executive summary

• Achieved record quarterly revenue of $7.9 million in Q2 2024, up 32% year-over-year, with all segments contributing to growth and gross margin improving to 63% from 53% year-over-year.

• Product revenue more than doubled to $4.9 million, Biologics and Drug Delivery revenue rose 28% to $4.3 million, and Neurosurgery Navigation and Therapy revenue increased 17% to $2.6 million.

• Operational cash burn reduced by 47% year-over-year to $2.7 million, and cash and cash equivalents increased to $32.8 million as of June 30, 2024.

• Expanded platform via advanced A.I., machine learning, and strategic partnerships, with over 85 neurosurgery and research centers using the platform and targeting 100+ by 2025.

• Total addressable market exceeds $12B across products, pipeline, and partnerships.

Financial highlights

• Q2 2024 revenue grew 32% year-over-year to $7.9 million; gross margin expanded to 63% from 53% in Q2 2023.

• Net loss for Q2 2024 was $4.4 million, an improvement from $7.1 million in Q2 2023; net loss per share was $0.16 vs. $0.29.

• Operating expenses decreased to $9.7 million from $10.3 million year-over-year; R&D costs down 13% to $3.1 million.

• Cash and cash equivalents at $32.8 million as of June 30, 2024, up from $23.1 million at year-end 2023, bolstered by a $16.2 million public stock offering in March 2024.

• Product revenue grew 112% to $4.9 million in Q2 2024; capital equipment and software revenue up 148% to $0.9 million.

Outlook and guidance

• Raised 2024 revenue guidance to $30–33 million, representing 25–38% annual growth, with cash flow breakeven targeted by end of 2025.

• Guidance range reflects timing uncertainty of large pharma service contracts and milestone-based revenue.

• Plans to achieve global scale with 100+ centers and expand product launches and software integrations in 2024 and 2025.